At the 2023 ASCO meeting, RudaCure registered an abstract for RCI002, its chemotherapy-induced traitement de la douleur compound, and presented the résultats précliniques of the drug to many international chercheurs.
En particulier, this attendance was dans le cadre de the KONECT essai clinique delegation, which provided a venue to discuss clinical topics related to ADC and CAR-T in the oncology field, along with related diseases and effets secondaires, ainsi que an opportunity to introduce the efficacy of RCI002 in traitement de la douleur.
RudaCure Clinical Director Yuseung Ha explaining RCI002 to a WRNMC Oncology Pharmacist
RCI002 Development Project Owner Manager Minjung Kim, Abbvie RA representative, WRNMC Pharmacist, Clinical Director Yuseung Ha
데일리팜: 데일리팜